In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

This was the stock's fifth consecutive day of losses.

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...

Galapagos (GLPG) stock is in focus as the company looks to amend its 10-year deal with Gilead (GILD) as part of plans to create a new listed unit. Read more here.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, "HOOKIPA", the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics ...

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

2025年1月7日，生物科技公司吉利德科学（GILD）成交额为5.28亿美元，在当日美股中排第156名，成交额较昨日减少14.50%，当日成交量为581.03万。 吉利德科学（GILD）于2025年1月7日跌0.66%，报90.63美元，该股过去5个交易日跌1.88%，整个1月跌1.88%，年初至今跌1.88%，过去52周涨7.91%。 *如果公司上市时间少于52周，则52周涨跌幅为上市至今涨跌幅 ...

This was the stock's fourth consecutive day of losses.

HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIPA of Poolbeg Pharma plc, which was announced on January ...